X

Drug Profile

Autologous cultured chondrocytes - Co.don AG

Alternative Names: ADCT; Chondrotransplant DISC; SpheChon; Spherox

Latest Information Update: 30 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator co.don AG
Developer co.don AG; ReLive Biotechnologies
Class Cell therapies
Mechanism of Action Chondrocytes replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Back pain
Registered Knee injuries

Most Recent Events

31 Dec 2023 Registered for Knee injuries (In adults, In adolescents) in Singapore (Intra-articular)
25 Jan 2023 ReLive Biotechnologies acquires "Spherox" and "Chondrosphere" from Co.don AG
20 May 2021 Preregistration for Knee injuries (In adolescents) in European Union (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com